A new peer-reviewed paper published in the journal Diabetes Therapy suggests that GLP-1 receptor agonists — the drug class behind Ozempic, Wegovy, and Zepbound — may play a meaningful role in slowing or even reversing prediabetes, a condition that affects millions and often quietly progresses to type 2 diabetes.
What the Research Found
The review examined existing evidence on using GLP-1 receptor agonists (GLP-1RAs) in people with prediabetes. According to the abstract, type 2 diabetes was less frequent among subjects taking liraglutide, semaglutide, and tirzepatide compared with those in the control arm of studied trials. The authors also found evidence of delayed progression to type 2 diabetes among those on these medications.
The authors describe the current evidence base as "limited, yet promising" — an important qualifier that signals this is an emerging area of research rather than a settled clinical consensus.
Why Prediabetes Matters
Prediabetes is a condition where blood sugar levels are elevated but not yet high enough to be classified as type 2 diabetes. The review notes it carries an increased risk of both type 2 diabetes and cardiovascular disease. Left unaddressed, prediabetes frequently advances to a full diabetes diagnosis — making early intervention a priority for many clinicians.
GLP-1 receptor agonists are already established as antidiabetic agents and are widely approved for obesity management. Their potential utility in prediabetes would represent an expansion of an already growing role in metabolic health.
Key takeaway: Research published in Diabetes Therapy found that liraglutide, semaglutide, and tirzepatide were each associated with lower rates of type 2 diabetes development compared to control groups — suggesting GLP-1 drugs may help prevent prediabetes from advancing.
What This Means If You Have Prediabetes
Currently, GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not specifically approved to treat prediabetes. However, this research adds to a growing body of evidence that may eventually shape prescribing guidelines. If you have prediabetes and are also managing obesity or weight concerns, these medications may already be relevant to your care — but that conversation belongs with your doctor.
It's also worth noting that lifestyle changes — diet and exercise — remain a cornerstone of prediabetes management and are not replaced by medication.
What to Watch Next
The review authors describe the evidence as promising but limited, suggesting larger and longer clinical trials focused specifically on prediabetes populations are needed. As GLP-1 drugs continue to be studied across a widening range of conditions, prediabetes is increasingly on researchers' radar. Future regulatory decisions could eventually expand approved indications for these medications.
Frequently Asked Questions
This research is an encouraging early signal, but individual circumstances vary widely. If you have prediabetes or are concerned about your diabetes risk, speak with your prescriber or a qualified healthcare professional to understand whether GLP-1 medications or other interventions are appropriate for your specific situation.
- Peer-reviewed journal article, 'Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes,' Diabetes Therapy, date not specified in source material.